Eduardo Esteve1, Wifredo Ricart, Jose-Manuel Fernández-Real. 1. Unit of Diabetes, Endocrinology and Nutrition, Biomedical Research Institute (IDIBGi), Hospital Dr Josep Trueta of Girona, Girona, Spain. eesteve.girona.ics@gencat.cat
Abstract
PURPOSE OF REVIEW: The prevalence of obesity, insulin resistance and type 2 diabetes has steadily increased in the last decades. In addition to the genetic and environmental factors, gut microbiota may play an important role in the modulation of intermediary phenotypes leading to metabolic disease. RECENT FINDINGS: Obesity and type 2 diabetes are associated with specific changes in gut microbiota composition. The mechanisms underlying the association of specific gut microbiota and metabolic disease include increasing energy harvest from the diet, changes in host gene expression, energy expenditure and storage, and alterations in gut permeability leading to metabolic endotoxemia, inflammation and insulin resistance. In some studies, the modifications of gut microbiota induced by antibiotics, prebiotics and probiotics led to improved inflammatory activity in parallel to amelioration of insulin sensitivity and decreased adiposity. However, these effects were mainly observed in animal models. Their extrapolation to humans awaits further studies. SUMMARY: The fascinating role of gut microbiota on metabolic disease opens new avenues in the treatment of obesity, insulin resistance and type 2 diabetes. A co-evolutionary clue for microbiota and insulin resistance is suggested.
PURPOSE OF REVIEW: The prevalence of obesity, insulin resistance and type 2 diabetes has steadily increased in the last decades. In addition to the genetic and environmental factors, gut microbiota may play an important role in the modulation of intermediary phenotypes leading to metabolic disease. RECENT FINDINGS:Obesity and type 2 diabetes are associated with specific changes in gut microbiota composition. The mechanisms underlying the association of specific gut microbiota and metabolic disease include increasing energy harvest from the diet, changes in host gene expression, energy expenditure and storage, and alterations in gut permeability leading to metabolic endotoxemia, inflammation and insulin resistance. In some studies, the modifications of gut microbiota induced by antibiotics, prebiotics and probiotics led to improved inflammatory activity in parallel to amelioration of insulin sensitivity and decreased adiposity. However, these effects were mainly observed in animal models. Their extrapolation to humans awaits further studies. SUMMARY: The fascinating role of gut microbiota on metabolic disease opens new avenues in the treatment of obesity, insulin resistance and type 2 diabetes. A co-evolutionary clue for microbiota and insulin resistance is suggested.
Authors: Miguel Á Martínez-González; Miguel Ruiz-Canela; Adela Hruby; Liming Liang; Antonia Trichopoulou; Frank B Hu Journal: J Nutr Date: 2015-04-01 Impact factor: 4.798
Authors: Ajay Kumar Jain; Carel W le Roux; Puneet Puri; Ali Tavakkoli; Nana Gletsu-Miller; Blandine Laferrère; Richard Kellermayer; John K DiBaise; Robert G Martindale; Bruce M Wolfe Journal: JPEN J Parenter Enteral Nutr Date: 2018-02 Impact factor: 4.016
Authors: Ajay Kumar Jain; Abhineet Sharma; Sumit Arora; Keith Blomenkamp; Ik Chan Jun; Robert Luong; David John Westrich; Aayush Mittal; Paula M Buchanan; Miguel A Guzman; John Long; Brent A Neuschwander-Tetri; Jeffery Teckman Journal: JPEN J Parenter Enteral Nutr Date: 2016-08-20 Impact factor: 4.016
Authors: Ajay P Belgaumkar; Royce P Vincent; Kirstin A Carswell; Robin D Hughes; Jamie Alaghband-Zadeh; Ragai R Mitry; Carel W le Roux; Ameet G Patel Journal: Obes Surg Date: 2016-06 Impact factor: 4.129